Global lab innovation specialist, Beckman Coulter, has launched a conjugated antibody for flow cytometry that will help clinical researchers identify T-cell neoplasms in areas like cancer research.
Traditional approaches to identifying clonal T-cell expansion have been complex and challenging, relying on the assessment of abnormal antigen expression, which is often difficult to see clearly and can overlap with reactive T-cell subsets.
B-cells can offer a richer and more simplistic solution, with the detection of clonal B-cell expansion enabled by the staining of both surface kappa and lambda immunoglobulin light chains utilizing flow cytometry.
The TCR constant β chains 1 and 2, or TRBC1 and TRBC2, are randomly selected during T-cell development in the thymus and are mutually exclusive.
Normal T-cell populations include a mix of the two, while clonal populations include only one. TRBC1 and TRBC2 staining using flow cytometry offers a low-cost, rapid, and specific T-cell clonality test.
Both can be conjugated to any dye in the Beckman Coulter Life Sciences portfolio through Custom Design Services either as a standalone conjugated antibody, or part of liquid or dry custom panels.
Pietro Lopriore, vice president and general manager of the Flow Cytometry Business Unit said,“Beckman Coulter Life Sciences has been committed to T-cell research for more than 25 years as we launched our Beta Mark TCR Vβ Repertoire Kit, and we’ve continued to innovate and raise the bar with solutions for this pioneering method to help labs ensure greater accuracy with fewer touchpoints.”
“This release creates a step forward in reducing complexities while providing clearer results in the important area of T-cell cancer research.”
Currently for Research Use Only (RUO), the company is pursuing development of a diagnostic version for commercial availability.
